{"commentary":{"count":116,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":46,"x_thread":41,"podcast":29},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05174169\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CIRCULATE-US","nct_id":"NCT05174169","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=circulate-us-nct05174169. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CIRCULATE-US","arms":[{"description":"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles\n\nOR\n\nOxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles","label":"Cohort A - Arm 1 (ctDNA-ve)","type":"ACTIVE_COMPARATOR"},{"description":"Serial ctDNA monitoring no treatment","label":"Cohort A - Arm 2 (ctDNA-ve)","type":"EXPERIMENTAL"},{"description":"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles\n\nOR\n\nOxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles","label":"Cohort B - Arm 3 (ctDNA+ve)","type":"ACTIVE_COMPARATOR"},{"description":"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles","label":"Cohort B - Arm 4 (ctDNA+ve)","type":"EXPERIMENTAL"}],"collaborators":["Natera, Inc.","National Cancer Institute (NCI)"],"completion_date":{"date":"2030-03-10","type":"ESTIMATED"},"conditions":["Stage III Colon Cancer"],"enrollment":{"count":1912,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Signatera test","type":"DEVICE"},{"name":"mFOLFOX6 3-6 month","type":"DRUG"},{"name":"CAPOX 3 month","type":"DRUG"},{"name":"mFOLFIRINOX","type":"DRUG"},{"name":"mFOLFOX6 6 month","type":"DRUG"},{"name":"CAPOX 6 month","type":"DRUG"}],"last_update":"2026-09-02","lead_sponsor":"NRG Oncology","official_title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-03-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"ctDNA positive status (TTPos)","timeFrame":"Time from randomization to the first TTPos event, a maximum of 3 years"},{"measure":"Disease-Free Survival (DFS)","timeFrame":"Time from randomization to disease-free survival event, a maximum of 5 years]"}],"references":[],"start_date":{"date":"2022-07-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","url":"https://clinicaltrials.gov/study/NCT05174169"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/circulate-us-nct05174169"}